IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.
About IPO Scanner
IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.
Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.
Details of client bank account
For any query / feedback / clarifications, email at
[email protected].
Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.
© 2026 IPO Scanner. All rights reserved.
Want to stay updated?Subscribe to our newsletter

Sector
Healthcare
Filed
Jul 15, 2026
Vogenx, Inc.
Vogenx is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis.
Our company was founded in 2021 by experienced leaders with proven expertise developing drugs in the metabolic disease space.
Our primary objective is to advance our lead investigational product candidate, mizagliflozin, a selective inhibitor of the sodium-glucose transporter 1, or SGLT1, through clinical development for disorders related to glucose absorption and postprandial dysregulation, through clinical development and towards regulatory approval.
Ticker, listing venue and issuer profile
Pricing terms and IPO milestones
Historical financial performance
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| S-1 | Jul 15, 2026 | General form for registration of securities under the Securities Act of 1933 |
| DRS/A | Jun 30, 2026 | [Amend] [Cover] Draft Registration Statement |
| DRS/A | Apr 2, 2026 | [Amend] [Cover] Draft Registration Statement |
| DRS | Feb 20, 2026 | [Cover] Draft Registration Statement |
| D | Jan 7, 2026 | Notice of Exempt Offering of Securities |
Contact and headquarters details
Key executives and officers
James Green
President, Chief Executive Officer and Director
William Wilkison, Ph.D.
Chief Scientific Officer and Director
Steven Delmar
Chief Financial Officer, Corporate Secretary and Director
Timothy Boris
Director
Richard Gorman
Director
Peter Pieraccini
Director